FI86146B - Foerfarande foer framstaellning av ett farmaceutiskt preparat med foerdroejd utloesning av ett aktiva aemnet och i preparatet anvaendbar baerare. - Google Patents
Foerfarande foer framstaellning av ett farmaceutiskt preparat med foerdroejd utloesning av ett aktiva aemnet och i preparatet anvaendbar baerare. Download PDFInfo
- Publication number
- FI86146B FI86146B FI863889A FI863889A FI86146B FI 86146 B FI86146 B FI 86146B FI 863889 A FI863889 A FI 863889A FI 863889 A FI863889 A FI 863889A FI 86146 B FI86146 B FI 86146B
- Authority
- FI
- Finland
- Prior art keywords
- tryptophan
- fumaric acid
- tablets
- ett
- release
- Prior art date
Links
- QIVBCDIJIAJPQS-UHFFFAOYSA-N tryptophan Chemical compound C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 102
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract description 92
- 239000003826 tablet Substances 0.000 claims abstract description 82
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 48
- 239000001530 fumaric acid Substances 0.000 claims abstract description 46
- 239000008187 granular material Substances 0.000 claims abstract description 37
- 239000013543 active substance Substances 0.000 claims abstract description 28
- 239000000829 suppository Substances 0.000 claims abstract description 14
- 239000002775 capsule Substances 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 27
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 12
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 claims description 9
- 229960002497 nicorandil Drugs 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000013268 sustained release Methods 0.000 claims description 9
- 239000012730 sustained-release form Substances 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000007891 compressed tablet Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 abstract description 26
- 239000003814 drug Substances 0.000 abstract description 11
- 239000000843 powder Substances 0.000 abstract description 11
- -1 troche Substances 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 10
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 150000001413 amino acids Chemical class 0.000 abstract description 2
- 150000007524 organic acids Chemical class 0.000 abstract description 2
- 235000005985 organic acids Nutrition 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 description 37
- 239000007788 liquid Substances 0.000 description 30
- 239000000126 substance Substances 0.000 description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 11
- 239000011812 mixed powder Substances 0.000 description 11
- 238000005303 weighing Methods 0.000 description 10
- 239000004698 Polyethylene Substances 0.000 description 9
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 9
- 239000008116 calcium stearate Substances 0.000 description 9
- 235000013539 calcium stearate Nutrition 0.000 description 9
- 230000000968 intestinal effect Effects 0.000 description 9
- 229920000573 polyethylene Polymers 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 238000007922 dissolution test Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 6
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 6
- 229960000212 aminophenazone Drugs 0.000 description 6
- 239000001856 Ethyl cellulose Substances 0.000 description 5
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 5
- 239000001354 calcium citrate Substances 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 229920001249 ethyl cellulose Polymers 0.000 description 5
- 235000019325 ethyl cellulose Nutrition 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 239000004570 mortar (masonry) Substances 0.000 description 5
- 235000013337 tricalcium citrate Nutrition 0.000 description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- 229910002651 NO3 Inorganic materials 0.000 description 4
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 239000008177 pharmaceutical agent Substances 0.000 description 4
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 4
- 229960002695 phenobarbital Drugs 0.000 description 4
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 3
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 229920003114 HPC-L Polymers 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 150000003927 aminopyridines Chemical class 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000008173 hydrogenated soybean oil Substances 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229960004499 scopolamine hydrobromide Drugs 0.000 description 2
- WTGQALLALWYDJH-MOUKNHLCSA-N scopolamine hydrobromide (anhydrous) Chemical compound Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-MOUKNHLCSA-N 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000007939 sustained release tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 102220570135 Histone PARylation factor 1_L30D_mutation Human genes 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100338513 Mus musculus Hdac9 gene Proteins 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 101100338514 Xenopus laevis hdac9 gene Proteins 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- CRVGKGJPQYZRPT-UHFFFAOYSA-N diethylamino acetate Chemical compound CCN(CC)OC(C)=O CRVGKGJPQYZRPT-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- DVQHRBFGRZHMSR-UHFFFAOYSA-N sodium methyl 2,2-dimethyl-4,6-dioxo-5-(N-prop-2-enoxy-C-propylcarbonimidoyl)cyclohexane-1-carboxylate Chemical compound [Na+].C=CCON=C(CCC)[C-]1C(=O)CC(C)(C)C(C(=O)OC)C1=O DVQHRBFGRZHMSR-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (12)
1. Farmaceutisk bärare att användas i ett farma-ceutiskt preparat med fördröjd utlösning av det aktiva 5 ämnet tillsanunans med ett eller flere farmakologiskt aktiva ämnen 1 en hait av ätminstone 10 % av preparatets totalvikt, kännetecknad därav, att den innehäller fumarsyra och/eller DL-tryptofan, förutsatt att kombinationen Nlcorandil och fumarsyra utesluts. 10
2. Bärare enligt patentkravet 1, känne tecknad därav, att den innehäller huvudsakligen DL-tryptofan.
3. Bärare enligt patentkravet 1, kännetecknad därav, att den innehäller huvudsaligen fu- 15 marsyra och DL-tryptofan.
4. Bärare enligt patentkravet 2 eller 3 att användas 1 kombination med Nlcorandil.
5. Bärare enligt patentkravet 1, kännetecknad därav, att den huvudsakligen innehäller 20 fumarsyra.
6. Användning av bäraren enligt patentkravet 1 i ett farmaceutiskt preparat, vilket är en komprimerad tab-lett eller en flerskiktstablett, som innehäller bärare enligt patentkravet 1 i ett eller flere skikt; ett läke- : 25 medelsgranulat, en kapsel eller en suppositorie.
7. Förfarande för framställning av ett farmaceutiskt preparat med fördröjd utlösning av det aktiva äm- : : net, kännetecknat därav, att man kombinerar en bärare innehällande fumarsyra och/eller DL-tryptofan . 30 och ett eller flere farmakologiskt användbara ämnen med undantag av att kombinera Nlcorandil och fumarsyra, sä ... ; att bäraren utgör minst 10 % av preparatets totalvikt.
8. Förfarande enligt patentkravet 7, k ä n n e - • · · *. tecknat därav, att man kombinerar DL-tryptofan med • '/· 35 ett eller flere aktiva ämnen. * « • · 22 861 46
9. Förfarande enligt patentkravet 7, känne-t e c k n a t därav, att bäraren innehäller fumarsyra och DL-tryptofan.
10. Förfarande enligt patentkravet 8 eller 9, 5 kännetecknat därav, att preparatet innehäller Nicorandil som farmakologiskt aktivt ämne.
11. Förfarande enligt patentkravet 7, känne-t e c k n a t därav, att man kombinerar fumarsyra och ett eller flere farmakologiskt aktiva ämnen förutom Nico- 10 randil.
12. Förfarande enligt patentkravet 7, känne-t e c k n a t därav, att man framställer en komprimerad tablett eller en flerskiktstablett, som innehäller fumarsyra och/eller DL-tryptofan i ett eller flere skikt; el- 15 ler ett granulat, en kapsel eller en suppositorie. I ·1 * » • » • · • · • « > · » m • « o • • · · »
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP21327785 | 1985-09-26 | ||
| JP21327785 | 1985-09-26 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI863889A0 FI863889A0 (fi) | 1986-09-26 |
| FI863889L FI863889L (fi) | 1987-03-27 |
| FI86146B true FI86146B (fi) | 1992-04-15 |
| FI86146C FI86146C (sv) | 1992-07-27 |
Family
ID=16636441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI863889A FI86146C (sv) | 1985-09-26 | 1986-09-26 | Förfarande för framställning av ett farmaceutiskt preparat med fördröj t utlösning av ett aktiva ämnet och i preparatet användbar bärare |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US5188840A (sv) |
| EP (2) | EP0386801B1 (sv) |
| JP (1) | JPH0772142B2 (sv) |
| KR (1) | KR950010145B1 (sv) |
| AT (2) | ATE62408T1 (sv) |
| AU (1) | AU587281B2 (sv) |
| CA (1) | CA1282327C (sv) |
| DE (2) | DE3678661D1 (sv) |
| DK (2) | DK166478B1 (sv) |
| ES (1) | ES2001993A6 (sv) |
| FI (1) | FI86146C (sv) |
| HK (1) | HK65393A (sv) |
| IE (2) | IE66255B1 (sv) |
| NO (1) | NO175763C (sv) |
| SG (1) | SG64993G (sv) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE8429928U1 (de) * | 1984-10-11 | 1986-02-13 | Sträter, Fritz, 5882 Meinerzhagen | Konzepthalter zur Anwendung an Schreib-, Zeichen-, Bildschirmarbeitsplätzen und dgl. |
| KR940000232B1 (ko) * | 1986-01-17 | 1994-01-12 | 쥬우가이세이야꾸 가부시끼가이샤 | 니코란딜 제제의 안정화 방법 |
| US5057317A (en) * | 1987-03-24 | 1991-10-15 | Chugai Seiyaku Kabushiki Kaisha | Slow-release pharmaceutical agent |
| CA1323833C (en) * | 1987-04-28 | 1993-11-02 | Yatindra M. Joshi | Pharmaceutical compositions in the form of beadlets and method |
| SE509029C2 (sv) * | 1988-08-16 | 1998-11-30 | Ss Pharmaceutical Co | Långtidsverkande diklofenak-natriumpreparat |
| IT1256022B (it) * | 1992-06-08 | 1995-11-20 | Preparazioni farmaceutiche stabili di nicorandil | |
| IT1255522B (it) * | 1992-09-24 | 1995-11-09 | Ubaldo Conte | Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita' |
| US6183778B1 (en) | 1993-09-21 | 2001-02-06 | Jagotec Ag | Pharmaceutical tablet capable of liberating one or more drugs at different release rates |
| US5602180A (en) * | 1995-03-31 | 1997-02-11 | World Health Group | Method of administering EDTA complexes |
| SG80553A1 (en) * | 1995-07-20 | 2001-05-22 | Tanabe Seiyaku Co | Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract |
| FR2742659B1 (fr) * | 1995-12-22 | 1998-03-13 | Pf Medicament | Procede de fabrication de minispheres matricielles a liberation prolongee |
| CA2305535A1 (en) * | 1997-10-03 | 1999-04-15 | Gopadi M. Venkatesh | Controlled release solid dosage forms of lithium carbonate |
| AU748359B2 (en) * | 1998-05-15 | 2002-06-06 | Chugai Seiyaku Kabushiki Kaisha | Controlled-release formulations |
| AU778049B2 (en) * | 1999-08-09 | 2004-11-11 | Dainippon Sumitomo Pharma Co., Ltd. | Solid preparation containing chitosan powder and process for producing the same |
| CN1228043C (zh) | 1999-09-30 | 2005-11-23 | 爱德华·孟岱尔股份有限公司 | 用于高溶解度药物的缓释基质 |
| JP4757995B2 (ja) * | 1999-11-10 | 2011-08-24 | 大日本住友製薬株式会社 | 薬物放出製剤 |
| DE10031043A1 (de) * | 2000-06-26 | 2002-02-14 | Bayer Ag | Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung |
| EP2135611A1 (en) | 2001-03-01 | 2009-12-23 | Hollis-Eden Pharmaceuticals Inc. | Pregn-5-en-20-yne-3,7,17-triol derivatives for use in therapy |
| US6720356B2 (en) * | 2001-04-20 | 2004-04-13 | Spencer Feldman | Magnesium di-potassium EDTA complex and method of administration |
| US7122143B2 (en) * | 2001-09-28 | 2006-10-17 | Mcneil-Ppc, Inc. | Methods for manufacturing dosage forms |
| US7838026B2 (en) | 2001-09-28 | 2010-11-23 | Mcneil-Ppc, Inc. | Burst-release polymer composition and dosage forms comprising the same |
| US7323192B2 (en) * | 2001-09-28 | 2008-01-29 | Mcneil-Ppc, Inc. | Immediate release tablet |
| CN1592610A (zh) | 2001-09-28 | 2005-03-09 | 麦克内尔-Ppc股份有限公司 | 改良的释放剂型 |
| US6837696B2 (en) * | 2001-09-28 | 2005-01-04 | Mcneil-Ppc, Inc. | Apparatus for manufacturing dosage forms |
| US20040166159A1 (en) * | 2002-05-29 | 2004-08-26 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa |
| US20060013875A1 (en) * | 2002-05-29 | 2006-01-19 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
| US7094427B2 (en) * | 2002-05-29 | 2006-08-22 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
| US20030224045A1 (en) * | 2002-05-29 | 2003-12-04 | Chien-Hsuan Han | Combination immediate release sustained release levodopa/carbidopa dosage forms |
| US20090035260A1 (en) * | 2002-07-29 | 2009-02-05 | Therapicon Srl | Enhanced nasal composition of active peptide |
| US7807197B2 (en) * | 2002-09-28 | 2010-10-05 | Mcneil-Ppc, Inc. | Composite dosage forms having an inlaid portion |
| US20040228918A1 (en) * | 2003-01-02 | 2004-11-18 | Chih-Ming Chen | Granule modulating hydrogel system |
| ITMI20040235A1 (it) * | 2004-02-13 | 2004-05-13 | Therapicon Srl | Preparazione farmaceutica per il cavo orale |
| DE102004039196B4 (de) | 2004-08-12 | 2008-07-31 | Dr.Kamprad Kg | Neue Formulierung für L-Tryptophan |
| CA2582231A1 (en) | 2004-09-29 | 2006-10-19 | Hollis-Eden Pharmaceuticals, Inc. | Steroid analogs and uses |
| US8673352B2 (en) * | 2005-04-15 | 2014-03-18 | Mcneil-Ppc, Inc. | Modified release dosage form |
| WO2013153210A1 (en) | 2012-04-13 | 2013-10-17 | Nanoscape Ag | Sustained-release formulation |
| US10987313B2 (en) | 2013-10-07 | 2021-04-27 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
| EP3782614A1 (en) | 2013-10-07 | 2021-02-24 | Impax Laboratories, LLC | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
| US11986449B2 (en) | 2020-12-22 | 2024-05-21 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
| EP4267113A4 (en) | 2020-12-22 | 2025-02-12 | Amneal Pharmaceuticals LLC | LEVODOPA DOSING SCHEME |
| CN117618376B (zh) * | 2023-12-11 | 2024-08-13 | 江苏诺和必拓新药研发有限公司 | 一种尼可地尔膜控缓释片及其制备方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES300432A1 (es) * | 1963-06-04 | 1964-11-16 | Abbott Lab | Procedimiento para producir una composición analgésica |
| US3577491A (en) * | 1968-01-02 | 1971-05-04 | Miles Lab | Tableting |
| US3849558A (en) * | 1969-06-03 | 1974-11-19 | Sumitomo Chemical Co | Pharmaceutical compositions having controlled gastro-intestinal absorption |
| US3608063A (en) * | 1969-08-15 | 1971-09-21 | Gilbert S Banker | Molecular drug entrapment process and compositions |
| BE759520A (fr) * | 1969-11-28 | 1971-04-30 | Aspro Nicholas Ltd | Compositions d'aspirine |
| US3903255A (en) * | 1971-05-17 | 1975-09-02 | Rohm & Haas | Effervescent potassium chloride tablet |
| JPS5115094B2 (sv) * | 1972-11-01 | 1976-05-14 | ||
| US3993999A (en) * | 1975-05-16 | 1976-11-23 | Texas Instruments Incorporated | Amplitude modulation scanning antenna system |
| US4021546A (en) * | 1976-03-08 | 1977-05-03 | Interx Research Corporation | Pro-drug forms of digoxin and method of preparing and using same |
| DE2656227C2 (de) * | 1976-12-11 | 1985-07-04 | Bayer Ag, 5090 Leverkusen | Basisch alkylierte Diphenyldisulfid-2,2'-biscarbonsäureamide, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel |
| GB1576376A (en) * | 1977-03-30 | 1980-10-08 | Benzon As Alfred | Multiple-unit drug dose |
| US4180559A (en) * | 1978-01-05 | 1979-12-25 | Richardson-Merrell Inc. | Coated 1-(2-chlorodibenzo[b,f]oxepin-10-yl)-4-methylpiperazine compositions |
| DE2841170A1 (de) * | 1978-09-21 | 1980-04-03 | Pharmazeutische Praeparate Apo | Hypnotikum |
| US4342764A (en) * | 1979-05-29 | 1982-08-03 | Ciba-Geigy Corporation | Guanidine compounds, pharmaceutical compositions and use |
| US4406896A (en) * | 1979-12-20 | 1983-09-27 | Merck & Co., Inc. | Adjuvants for rectal delivery of drug substances |
| DE3011327A1 (de) * | 1980-03-24 | 1981-10-01 | Basf Ag, 6700 Ludwigshafen | 1-aroyl-2-phenylamino-2-imidazoline, ihre herstellung und verwendung |
| ZA823333B (sv) * | 1981-04-24 | 1983-11-14 | ||
| IT1198386B (it) * | 1982-07-06 | 1988-12-21 | Lepetit Spa | Un prodotto a rilascio protratto contenente il suloctidile |
| US4704284A (en) * | 1982-08-12 | 1987-11-03 | Pfizer Inc. | Long-acting matrix tablet formulations |
| US4503031A (en) * | 1982-12-17 | 1985-03-05 | Glassman Jacob A | Super-fast-starting-sustained release tablet |
| KR880002139B1 (ko) * | 1983-04-08 | 1988-10-17 | 베링거 인겔하임 리미티드 | 경구 투여용 정제의 제조방법 |
| PH18946A (en) * | 1983-04-21 | 1985-11-14 | Elan Corp Plc | Controlled absorption pharmaceutical composition |
| DE3315797A1 (de) * | 1983-04-30 | 1984-10-31 | Beiersdorf Ag, 2000 Hamburg | Substituierte phenyl-2-(1h)-pyrimidinone, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen |
| US4530920A (en) * | 1983-11-07 | 1985-07-23 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist |
| JPH0653658B2 (ja) * | 1984-12-17 | 1994-07-20 | 中外製薬株式会社 | 安定な錠剤の製造法 |
| FR2588559B1 (fr) * | 1985-10-11 | 1988-03-11 | Bp Chimie Sa | Procede de polymerisation ou de copolymerisation d'alpha-olefines en presence d'un systeme catalytique ziegler-natta ameliore |
-
1986
- 1986-09-15 US US06/906,959 patent/US5188840A/en not_active Expired - Lifetime
- 1986-09-16 IE IE940953A patent/IE66255B1/en not_active IP Right Cessation
- 1986-09-16 IE IE246886A patent/IE81099B1/en not_active IP Right Cessation
- 1986-09-16 AU AU62730/86A patent/AU587281B2/en not_active Expired
- 1986-09-24 NO NO863796A patent/NO175763C/no not_active IP Right Cessation
- 1986-09-24 DK DK455286A patent/DK166478B1/da not_active IP Right Cessation
- 1986-09-25 AT AT86113193T patent/ATE62408T1/de not_active IP Right Cessation
- 1986-09-25 EP EP90107877A patent/EP0386801B1/en not_active Expired - Lifetime
- 1986-09-25 ES ES8602189A patent/ES2001993A6/es not_active Expired
- 1986-09-25 DE DE8686113193T patent/DE3678661D1/de not_active Expired - Lifetime
- 1986-09-25 EP EP86113193A patent/EP0218148B1/en not_active Expired - Lifetime
- 1986-09-25 CA CA000519060A patent/CA1282327C/en not_active Expired - Lifetime
- 1986-09-25 JP JP61226468A patent/JPH0772142B2/ja not_active Expired - Fee Related
- 1986-09-25 AT AT90107877T patent/ATE108647T1/de not_active IP Right Cessation
- 1986-09-25 DE DE3689983T patent/DE3689983T2/de not_active Expired - Lifetime
- 1986-09-26 FI FI863889A patent/FI86146C/sv not_active IP Right Cessation
- 1986-09-26 KR KR1019860008085A patent/KR950010145B1/ko not_active Expired - Fee Related
-
1992
- 1992-08-31 DK DK108192A patent/DK170110B1/da not_active IP Right Cessation
-
1993
- 1993-05-18 SG SG64993A patent/SG64993G/en unknown
- 1993-07-08 HK HK653/93A patent/HK65393A/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI86146B (fi) | Foerfarande foer framstaellning av ett farmaceutiskt preparat med foerdroejd utloesning av ett aktiva aemnet och i preparatet anvaendbar baerare. | |
| KR100203339B1 (ko) | 의약용 방출조절 매트릭스 | |
| US5445829A (en) | Extended release pharmaceutical formulations | |
| AU741361B2 (en) | Modified release matrix formulation of cefaclor and cephalexin | |
| FI94094C (sv) | Bärarkomposition för läkemedelspreparat med fördröjd verkan | |
| AU2001260212C1 (en) | Composition | |
| KR20050083816A (ko) | 24시간 효능의 서방 트라마돌 조성물 | |
| CN101351196A (zh) | 作为胶囊填充物的基于亲脂性载体的双重控释基质系统 | |
| EP2726064B1 (en) | Controlled release oral dosage form comprising oxycodone | |
| MXPA05004412A (es) | Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas. | |
| KR20120130761A (ko) | 라미프릴 및 암로디핀 베실레이트의 고형 약제학적 제형, 및 이의 제조 | |
| EP2386302A1 (en) | A controlled release pharmaceutical dosage form of trimetazidine and processes for the preparation thereof | |
| JP2535141B2 (ja) | フマル酸含有徐放性製剤 | |
| EP4313014A1 (en) | A method for the production of gastroretentive compact matrices for the controlled release of active substances and compact matrices thus obtained | |
| CA2328102A1 (en) | New pharmaceutical formulation | |
| CN1172429A (zh) | 使用从高等植物中可得到的粉末状水解胶体树胶的持续释放药物运送体系 | |
| Srinivas et al. | Analytical Validation and Development of Cefixime Drug Substances in Pharmaceutical Formulations by Gas Chromatography | |
| GB2334212A (en) | Modified release matrix formulation for cefaclor and cephalexin | |
| BG66008B1 (bg) | Лекарствен препарат с изменено освобождаване | |
| AU2003285739A1 (en) | Extended release venlafaxine tablet formulation | |
| WO2016042563A1 (en) | Extended release formulation of carba-mazepine | |
| WO2013007360A1 (en) | Controlled release pharmaceutical composition of non-ergoline dopamine agonist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Owner name: CHUGAI SEIYAKU KABUSHIKI KAISHA |
|
| MA | Patent expired |